2019 Vaccine Guide & Insert - VG5

Routine vaccination

02/19/19

Special situations for MenACWY

cell disease), persistent complement component
deficiency, eculizumab use, microbiologists
routinely exposed to Neisseria meningitidis: 2-dose
series MenB-4C (Bexsero) at least 1 month apart,
or 3-dose series MenB-FHbp (Trumenba) at 0, 1-2,
6 months (if dose 2 was administered at least 6 months
after dose 1, dose 3 not needed); MenB-4C and MenBFHbp are not interchangeable (use same product for
all doses in series)
y Pregnancy: Delay MenB until after pregnancy unless
at increased risk and vaccination benefit outweighs
potential risks
y Healthy adolescents and young adults age
16 through 23 years (age 16 through 18 years
preferred) not at increased risk for meningococcal
disease: Based on individual clinical decision, may
receive 2-dose series MenB-4C at least 1 month apart,
or 2-dose series MenB-FHbp at 0, 6 months (if dose
2 was administered less than 6 months after dose
1, administer dose 3 at least 4 months after dose 2);
MenB-4C and MenB-FHbp are not interchangeable
(use same product for all doses in series)

y Anatomical or functional asplenia (including sickle

Special situations for MenB

cell disease), HIV infection, persistent complement
component deficiency, eculizumab use: 2-dose
series MenACWY (Menactra, Menveo) at least 8 weeks
apart and revaccinate every 5 years if risk remains
y Travel in countries with hyperendemic or epidemic
meningococcal disease, microbiologists routinely
exposed to Neisseria meningitidis: 1 dose MenACWY
and revaccinate every 5 years if risk remains
y First-year college students who live in residential
housing (if not previously vaccinated at age
16 years or older) and military recruits: 1 dose
MenACWY

*

To Fax: 1.800.329.9109 24 Hrs

Centers for Disease Control and Prevention | Recommended Adult Immunization Schedule, United States, 2019 | Page 5

rubella: MMR contraindicated during pregnancy; after
pregnancy (before discharge from health care facility),
1 dose MMR
y Non-pregnant women of childbearing age with no
evidence of immunity to rubella: 1 dose MMR
y HIV infection with CD4 count ≥200 cells/μL for at
least 6 months and no evidence of immunity to
measles, mumps, or rubella: 2-dose series MMR
at least 4 weeks apart; MMR contraindicated in HIV
infection with CD4 count <200 cells/μL
y Severe immunocompromising conditions: MMR
contraindicated
y Students in postsecondary educational
institutions, international travelers, and household
or close personal contacts of immunocompromised
persons with no evidence of immunity to measles,
mumps, or rubella: 1 dose MMR if previously received
1 dose MMR, or 2-dose series MMR at least 4 weeks
apart if previously did not receive any MMR
y Health care personnel born in 1957 or later with
no evidence of immunity to measles, mumps, or
rubella: 2-dose series MMR at least 4 weeks apart for
measles or mumps, or at least 1 dose MMR for rubella;
if born before 1957, consider 2-dose series MMR at
least 4 weeks apart for measles or mumps, or 1 dose
MMR for rubella

y Pregnancy with no evidence of immunity to

Special situations

rubella: 1 dose MMR
- Evidence of immunity: Born before 1957 (except
health care personnel [see below]), documentation
of receipt of MMR, laboratory evidence of immunity
or disease (diagnosis of disease without laboratory
confirmation is not evidence of immunity)

y Anatomical or functional asplenia (including sickle

Routine vaccination

y No evidence of immunity to measles, mumps, or

To Order: 1.800.P.SCHEIN (1.800.772.4346) 8am-8:30pm, et

angioedema, respiratory distress): 1 dose IIV, RIV, or
LAIV appropriate for age and health status annually
in medical setting under supervision of health care
provider who can recognize and manage severe
allergic conditions
y Immunocompromising conditions (including HIV
infection), anatomical or functional asplenia,
pregnant women, close contacts and caregivers
of severely immunocompromised persons
in protected environment, use of influenza
antiviral medications in previous 48 hours, with
cerebrospinal fluid leak or cochlear implant: 1 dose
IIV or RIV annually (LAIV not recommended)
y History of Guillain-Barré syndrome within 6 weeks
of previous dose of influenza vaccine: Generally
should not be vaccinated

y Egg allergy more severe than hives (e.g.,

appropriate for age and health status annually

y Egg allergy, hives only: 1 dose IIV, RIV, or LAIV

Special situations

professionals/index.htm

y For additional guidance, see www.cdc.gov/flu/

LAIV appropriate for age and health status annually

y Persons age 6 months or older: 1 dose IIV, RIV, or

Meningococcal vaccination

Measles, mumps, and rubella vaccination

Recommended Adult Immunization Schedule
United States, 2019

Influenza vaccination

Notes
http://www.cdc.gov/flu/profesionals/index.html http://www.cdc.gov/flu/profesionals/index.html
2019 Vaccine Guide & Insert

Table of Contents for the Digital Edition of 2019 Vaccine Guide & Insert
